Travere Therapeutics, Inc.
TVTX Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$50.08
KIRA · Stoqly’s AI analyst, in plain words
- Travere Therapeutics, Inc. had $491M of revenue in fiscal 2025, up 110.5% on the year before. Over five years, revenue changed +19.9% a year on average.
- Its operating margin was −12.8%, up 126.1 pts: of every 100 in sales, about −13 is left after running the business.
- Travere Therapeutics, Inc. lost $25.5M in fiscal 2025.
Market cap
$4.7B
P/E
—
Revenue
$491M
Net income
−$25.5M
Free cash flow
—
Operating margin
−12.8%
Travere Therapeutics, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+110.5%
Yes. Sales grew 110.5% last year.
Does it make a profit?
−5.2%
No. It lost money last year.
How healthy are the accounts?
6 / 8
Mixed. It passes 6 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Travere Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 19, 2026
- Legal name
- Travere Therapeutics, Inc.
- CIK
- 0001438533
Travere Therapeutics, Inc. · TVTX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $132M | $109M | $145M | $233M | $491M |
| Revenue growth | −33.5% | −17.0% | 32.7% | 60.5% | 110.5% |
| Gross margin | 97.1% | 96.0% | 92.1% | 96.7% | 97.9% |
| Operating margin | −151.3% | −292.2% | −267.2% | −138.9% | −12.8% |
| Net income | −$180M | −$278M | −$111M | −$322M | −$25.5M |
| Net margin | −136.6% | −254.4% | −76.7% | −137.9% | −5.2% |
| Diluted EPS | −$3.01 | −$4.37 | −$1.50 | −$4.08 | −$0.29 |
| Cash | |||||
| Cash from operations | −$14.8M | −$186M | −$280M | −$237M | $37.8M |
| Capital expenditure | $5.1M | $0.2M | $0.7M | — | — |
| Free cash flow | −$19.9M | −$186M | −$281M | — | — |
| FCF margin | −15.1% | −170.4% | −193.3% | — | — |
| Share count change | 25.9% | 6.6% | 16.5% | 6.2% | 13.1% |
| Debt and strength | |||||
| Cash and short-term investments | $428M | $347M | $307M | $58.5M | $238M |
| Shareholders' equity | $302M | $42.9M | $201M | $59.1M | $115M |
| Current ratio | 4.7x | 3.4x | 3.5x | 2.1x | 2.7x |
| Interest coverage | −10.1x | −29.1x | −34.3x | −29.0x | −5.8x |
| Returns and quality | |||||
| Return on equity | −70.2% | −161.5% | −91.4% | −247.4% | −29.4% |
| Return on tangible equity | −117.9% | — | −116.6% | — | −2,661.0% |
| Piotroski F-score | 4 | 1 | 3 | 3 | 6 |
| Altman Z'' | −0.4 | −4.7 | −3.9 | −9.1 | −5.4 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$117M
11 insiders
Of sales under plans
99%
$116M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Travere Therapeutics, Inc. · TVTX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $50.08 a share, the company is worth $4.7B.
Source: SEC EDGAR XBRL filings (CIK 0001438533). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.